Tag: Cancer Therapy
-
Organoids Reveal Glioblastoma’s Evasion Tricks in Brain-Murking Mini-Tumors
New 3D organoid models bring glioblastoma closer to the living brain Glioblastoma, the most aggressive form of brain cancer, has long shown a stubborn resistance to treatments. Researchers at UCLA have developed advanced miniature 3D tumor organoid models that mirror many aspects of human brain tissue. These organoids recreate the complex interactions between glioblastoma cells…
-
Customizable protein platforms offer new hope for cancer treatment
Revolutionary protein platforms target cancer at the source Researchers at the University of Massachusetts Amherst have developed customizable protein platforms that can precisely target cancer-causing proteins within malignant cells. By designing proteins that can shred, repair, or replace specific cellular components, this approach aims to halt tumor growth while sparing healthy tissue. The work represents…
-
Customizable Protein Platforms: A New Horizon for Cancer Therapy and Beyond
Introduction: A breakthrough in targeted cancer therapy Researchers at the University of Massachusetts Amherst are advancing customizable protein platforms designed to precisely shred or repair cancer-causing proteins within malignant cells. This innovative approach aims to offer targeted therapies that minimize collateral damage to healthy cells, addressing a longstanding challenge in oncology. While the immediate focus…
-
Purdue’s LENN System Improves Stability and Targeting of mRNA Cancer Therapies
Revolutionizing mRNA Cancer Therapy Delivery Researchers at Purdue University have unveiled a patent-pending, virus-mimicking platform called the LENN system, designed to enhance the stability and precision of messenger RNA (mRNA) therapies targeting cancer cells. In a field where delivery efficiency and targeted expression can determine treatment outcomes, LENN represents a compelling step forward for mRNA-based…
-
Living Drug Heralds Breakthrough in Aggressive Blood Cancer Treatment on the NHS
New Hope on the NHS: A Living Drug for Aggressive Leukemia A groundbreaking treatment described as a “living drug” has started to change the conversation around aggressive blood cancers in the UK. The first leukemia patient to receive this innovative therapy since its NHS rollout has reported a markedly positive experience, calling the treatment “fantastic”…
-
Mapping metastasis: how nutrient availability shapes breast cancer’s spread
Understanding how breast cancer metastasizes Breast cancer remains a leading cause of cancer-related mortality, in part because malignant cells can migrate from the primary tumor to distant organs. A growing body of research shows that where cancer cells settle is not random. The nutrient landscape of each organ—its available sugars, amino acids, lipids, and other…
-
The Dual Role of SLC7A11 in Colorectal Cancer Ferroptosis: From Molecules to Therapies
Understanding Ferroptosis and SLC7A11 Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation. In colorectal cancer (CRC), ferroptosis represents a promising avenue to overcome resistance to conventional therapies. Central to this process is SLC7A11, a component of the cystine/glutamate antiporter system Xc–, which imports cystine into cells in exchange for glutamate.…
-
BioLineRx Wins USPTO Allowance for GLIX1 Cancer Therapy Patent
BioLineRx Announces USPTO Notice of Allowance for GLIX1 Patent BioLineRx has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent covering the company’s GLIX1 program. This milestone strengthens the intellectual property framework around GLIX1, a molecule aimed at treating a broad range of cancers.…
-
BioLineRx GLIX1 Patent Receipt: USPTO Notice of Allowance Expands Cancer Treatment Reach
BioLineRx Secures USPTO Notice of Allowance for GLIX1 Patent BioLineRx announced a pivotal milestone: the U.S. Patent and Trademark Office has issued a Notice of Allowance for the GLIX1 patent, covering its use in treating a broad spectrum of cancers. This development marks a significant step in protecting the company’s GLIX1-based therapeutic approach as it…
-
BioLineRx Wins USPTO Notice of Allowance for GLIX1 Cancer Therapy Patent Across Most Cancers
Overview: A Major Step Forward for GLIX1 BioLineRx announced a significant milestone in its cancer therapy program with a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its key patent covering GLIX1. This development marks an important expansion of protection for GLIX1 as a potential treatment for a broad range…